Renal Dialysis Clinical Trial
Official title:
Is Reiki Effective In Coping With the Symptoms Experienced by Patients Undergoing Hemodialysis?: Single-Blind Randomized Controlled Trial
Verified date | April 2023 |
Source | Osmaniye Korkut Ata University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to investigate the effect of Reiki applied to individuals receiving hemodialysis treatment on hemodialysis-related symptoms and hematological indicators.
Status | Completed |
Enrollment | 64 |
Est. completion date | July 8, 2022 |
Est. primary completion date | June 13, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - To be over 18 years of age, - To have received hemodialysis treatment for at least 15 days, - To volunteer to participate in the study, - To be able to answer the given forms and questionnaires Exclusion Criteria: - To be a Reiki practitioner or trainer, - To have attended any energy therapy session before, - Using other complementary and integrative medicine practices at the time of the application. |
Country | Name | City | State |
---|---|---|---|
Turkey | Osmaniye Korkut Ata University | Osmaniye |
Lead Sponsor | Collaborator |
---|---|
Osmaniye Korkut Ata University |
Turkey,
Daniel P. Wirth, R. J. Chang, W. S. Eidelman & J. B. Paxton, Hematological Indicators of Complementary Healing Intervention, Complementary Therapies in Medicine 4 (996), pp. 4-20.
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. Erratum In: J Am Soc Nephrol. 2013 Dec;24(12):2127-9. — View Citation
Dyer NL, Baldwin AL, Rand WL. A Large-Scale Effectiveness Trial of Reiki for Physical and Psychological Health. J Altern Complement Med. 2019 Dec;25(12):1156-1162. doi: 10.1089/acm.2019.0022. Epub 2019 Oct 22. — View Citation
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021 Aug 28;398(10302):786-802. doi: 10.1016/S0140-6736(21)00519-5. Epub 2021 Jun 24. — View Citation
Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, Tangri N. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014 May;63(5):789-97. doi: 10.1053/j.ajkd.2013.12.012. Epub 2014 Feb 12. — View Citation
Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, Kumaraswami L, Liakopoulos V, Rakhimova Z, Saadi G, Strani L, Ulasi I, Kalantar-Zadeh K. Kidney health for everyone everywhere - from prevention to detection and equitable access to care. Clin Nephrol. 2020 Mar;93(3):111-122. doi: 10.5414/CNWKDEditorial. — View Citation
Lu PH, Yu MC, Wei MJ, Kuo KL. The Therapeutic Strategies for Uremic Toxins Control in Chronic Kidney Disease. Toxins (Basel). 2021 Aug 17;13(8):573. doi: 10.3390/toxins13080573. — View Citation
Muhith A, Hidayaah N, Faizah I, Sari, RY, Hartadi H. The Effect of Reiki Therapy on Posttraumatic Growth (Ptg) Among Chronic Renal Failure Patients Through Hemodialysis. Nurse and Health: Journal Keperawatan. 2021, 10(2): 190-200. http://ejournal-kertacendekia.id/index.php/nhjk/index
Önsöz HB, Usta Yesilbalkan Ö. Reliability and validity of the Turkish version of the dialysis symptom index in chronic hemodialysis patients. Turkish Nephrology, Dialysis and Transplantation Journal 2013; 22(1): 60-67
Vanholder RC, Eloot S, Glorieux GL. Future Avenues to Decrease Uremic Toxin Concentration. Am J Kidney Dis. 2016 Apr;67(4):664-76. doi: 10.1053/j.ajkd.2015.08.029. Epub 2015 Oct 21. — View Citation
Weisbord SD, Fried LF, Arnold RM, Rotondi AJ, Fine MJ, Levenson DJ, Switzer GE. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage. 2004 Mar;27(3):226-40. doi: 10.1016/j.jpainsymman.2003.07.004. — View Citation
Yu IC, Fang JT, Tsai YF. Exploring demands of hemodialysis patients in Taiwan: A two-step cluster analysis. PLoS One. 2020 Feb 7;15(2):e0228259. doi: 10.1371/journal.pone.0228259. eCollection 2020. — View Citation
Zarantonello D, Rhee CM, Kalantar-Zadeh K, Brunori G. Novel conservative management of chronic kidney disease via dialysis-free interventions. Curr Opin Nephrol Hypertens. 2021 Jan;30(1):97-107. doi: 10.1097/MNH.0000000000000670. — View Citation
Zins S, Hooke MC, Gross CR. Reiki for Pain During Hemodialysis: A Feasibility and Instrument Evaluation Study. J Holist Nurs. 2019 Jun;37(2):148-162. doi: 10.1177/0898010118797195. Epub 2018 Aug 31. — View Citation
* Note: There are 14 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Dialysis Symptom Index at a week | The Dialysis Symptom Index was used to investigate the therapeutic effect of Reiki on hemodialysis-related symptoms. The index consists of 30 items to evaluate physical and emotional symptoms and the severity of these symptoms. Participants are asked to define the presence of each symptom they experienced in the last week as Yes or No, and they are also report how much symptoms they experience affect them on a five-point Likert type scale (1 = not at all bothersome, 5 = very much bothersome). The lowest score to be obtained from the index is 0, the highest score is 150, and higher scores indicate more dialysis symptoms. In order to reach the Primary Outcome Measure, it was aimed that the Dialysis Symptom Index total scores of the individuals in the intervention group were lower in the final measurement than in the first measurement. | Within 1 hour of first admission. -A week later | |
Secondary | Change from Sodium values at a week | In this section there is Sodium value required for eliminating fluid-electrolyte imbalances. The observed sodium is expected to be 136 -144 mmol/L. | Within one week of first application | |
Secondary | Change from Potassium values at a week | In this section there is Potassium value required for eliminating fluid-electrolyte imbalances. The observed sodium is expected to be 3.7 - 5.1 mmol/L | Within one week of first application | |
Secondary | Change from Calcium values at a week | In this section there is Calcium value required for eliminating fluid-electrolyte imbalances. The observed Calcium is expected to be 8.5 -10.2 mg/dL | Within one week of first application | |
Secondary | Change from Chloride values at a week | In this section there is Chloride value required for eliminating fluid-electrolyte imbalances. The observed Chloride is expected to be 97 - 105 mmol/L | Within one week of first application | |
Secondary | Change from Magnesium values at a week | In this section there is Magnesium value required for eliminating fluid-electrolyte imbalances. The observed Magnesium is expected to be 1.7- 2.2 mg/dL | Within one week of first application | |
Secondary | Change from Phosphate values at a week | In this section there is Phosphate value required for eliminating fluid-electrolyte imbalances. The observed Phosphate is expected to be 2.5- 4.8 mg/dL | Within one week of first application | |
Secondary | Change from urea values at a week | In this section there is urea value required for eliminating fluid-electrolyte imbalances. The observed urea is expected to be 1.8 to 7.1 mmol | Within one week of first application | |
Secondary | Change from Hemoglobin values at a week | In this section there is Hemoglobin value required for preventing anemia. The observed Hemoglobin is expected to be Male (ages 15+): 13.0 - 17.0 g/dL; Female (ages 15+): 11.5 - 15.5 g/dL | Within one week of first application | |
Secondary | Change from Hematocrit values at a week | This section contains the Hematocrit value, which should be in the appropriate range to prevent fluid imbalance and anemia. The observed Hematocrit is expected to be Male: 40 - 55%; Female: 36 - 48% | Within one week of first application |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05189795 -
The Construction of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients
|
||
Completed |
NCT01125202 -
Intervention to Reduce Dietary Sodium in Hemodialysis
|
N/A | |
Completed |
NCT00730145 -
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
|
Phase 1 | |
Completed |
NCT00806130 -
Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
|
||
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Completed |
NCT05718765 -
The Effect of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients
|
N/A | |
Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
Completed |
NCT05469620 -
Adaptive Nutrition Therapy in Hemodialysis
|
N/A | |
Completed |
NCT03536858 -
Social Networks and Renal Education: Promoting Transplantation
|
N/A | |
Completed |
NCT00824837 -
Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane
|
Phase 1/Phase 2 | |
Completed |
NCT03403491 -
Study of Self-monitoring of Weight & Blood Pressure (Via patientMpower Platform) in Hemodialysis
|
N/A | |
Terminated |
NCT02495662 -
The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation
|
Phase 2 | |
Completed |
NCT01179620 -
Certoparin in Renal Patients Undergoing Hemodialysis
|
Phase 3 | |
Completed |
NCT01017276 -
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
|
Phase 3 | |
Active, not recruiting |
NCT04466865 -
A Communication Tool to Assist Older Adults Facing Dialysis Choices
|
N/A | |
Recruiting |
NCT03782519 -
Quality of Life of Frail Aged Patients in Incremental Hemodialysis
|
N/A | |
Recruiting |
NCT02843334 -
Study of the Prevalence of Fabry Disease in French Dialysis Patients
|
N/A | |
Recruiting |
NCT02545530 -
Transdermal Clonidine in Chronic Hemodialysis Patients
|
N/A | |
Completed |
NCT00892749 -
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
|
Phase 3 | |
Completed |
NCT00649298 -
A Clinical Trial of IntensiVE Dialysis
|
Phase 4 |